» Articles » PMID: 38348803

Incidental Arrhythmias During Atrial Fibrillation Screening With Repeat 7-Day Holter ECGs in a Hospital-Based Patient Population

Abstract

Background: Screening for atrial fibrillation (AF) may reveal incidental arrhythmias of relevance. The aim of this study was to describe incidental arrhythmias detected during screening for AF in the STAR-FIB (Predicting SilenT AtRial FIBrillation in Patients at High Thrombembolic Risk) cohort study.

Methods And Results: In the STAR-FIB cohort study, we screened hospitalized patients for AF with 3 repeat 7-day Holter ECGs. We analyzed all Holter ECGs for the presence of the following incidental arrhythmias: (1) sinus node dysfunction, defined as sinus pause of ≥3 seconds' duration; (2) second-degree (including Wenckebach) or higher-degree atrioventricular block (AVB); (3) sustained supraventricular tachycardia of ≥30 seconds' duration; and (4) sustained ventricular tachycardia of ≥30 seconds' duration. We furthermore report treatment decisions because of incidental arrhythmias. A total of 2077 Holter ECGs were performed in 794 patients (mean age, 74.7 years; 49% women), resulting in a mean cumulative duration of analyzable ECG signal of 414±136 hours/patient. We found incidental arrhythmias in 94 patients (11.8%). Among these were sinus node dysfunction in 14 patients (1.8%), AVB in 41 (5.2%), supraventricular tachycardia in 42 (5.3%), and ventricular tachycardia in 2 (0.3%). Second-degree AVB was found in 23 patients (2.9%), 2:1 AVB in 10 (1.3%), and complete AVB in 8 (1%). Subsequently, 8 patients underwent pacemaker implantation, 1 for sinus node dysfunction (post-AF conversion pause of 9 seconds) and 7 for advanced AVB. One patient had an implantable cardioverter-defibrillator implanted for syncopal ventricular tachycardia.

Conclusions: Incidental arrhythmias were frequently detected during screening for AF in the STAR-FIB study and resulted in device therapy in 1.1% of our cohort patients.

References
1.
Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M . Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet. 2021; 398(10310):1498-1506. DOI: 10.1016/S0140-6736(21)01637-8. View

2.
Perez M, Mahaffey K, Hedlin H, Rumsfeld J, Garcia A, Ferris T . Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019; 381(20):1909-1917. PMC: 8112605. DOI: 10.1056/NEJMoa1901183. View

3.
Diederichsen S, Xing L, Frodi D, Kongebro E, Haugan K, Graff C . Prevalence and Prognostic Significance of Bradyarrhythmias in Patients Screened for Atrial Fibrillation vs Usual Care: Post Hoc Analysis of the LOOP Randomized Clinical Trial. JAMA Cardiol. 2023; 8(4):326-334. PMC: 9932940. DOI: 10.1001/jamacardio.2022.5526. View

4.
Roten L, Goulouti E, Lam A, Elchinova E, Nozica N, Spirito A . Age and Sex Specific Prevalence of Clinical and Screen-Detected Atrial Fibrillation in Hospitalized Patients. J Clin Med. 2021; 10(21). PMC: 8584962. DOI: 10.3390/jcm10214871. View

5.
Thomsen P, Jons C, Raatikainen M, Joergensen R, Hartikainen J, Virtanen V . Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction: the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA).... Circulation. 2010; 122(13):1258-64. DOI: 10.1161/CIRCULATIONAHA.109.902148. View